NewsRadio WFLA (WFLA-AM)
NewsRadio WFLA (WFLA-AM)
DR. NIKHIL PALEKAR – NEW ALZHEIMER’S DRUG GETS FDA APPROVAL - 7 27 24
DR. NIKHIL PALEKAR – NEW ALZHEIMER’S DRUG GETS FDA APPROVAL - 7 27 24
DR. NIKHIL PALEKAR – NEW ALZHEIMER’S DRUG GETS FDA APPROVAL - 7 27 24
Saturday 27th July 2024
Dr. Nikhil Palekar discusses new FDA-approved Alzheimer's drugs, Lecanemab and Donanemab, offering hope by slowing disease progression.
Explicit
10 minutes
Informative
Hopeful
Encouraging
Educational
Supportive
About this podcast
Author:
NewsRadio WFLA (WFLA-AM)
Overview:
Categories:
Innovative Treatments & Recovery Paths
Holistic Health Innovations
Innovative Healing Arts
Sexual Stigmas & Myths
Mindful Recovery
Links:
Visit site
Episodes:
1002 (View all)
Do you want to link to this podcast?
Get the buttons here!New Hope for Alzheimer's: FDA Approves Groundbreaking Drugs
Episode Overview
- FDA has approved two new drugs for early-stage Alzheimer's: Lecanemab and Donanemab.
- These drugs target and remove amyloid plaques in the brain, slowing disease progression.
- Lecanemab shows a 27% reduction in symptoms; Donanemab shows a 35% reduction.
- Concerns about side effects like brain swelling are addressed with careful monitoring.
- Medicare covers a significant portion of treatment costs, making it more accessible.
These new medications go and bind to these amyloid plaques in the brain and remove them completely from the brain, thus slowing the progression of symptoms in patients with early stage Alzheimer's
In this episode of American Medicine Today, hosts Kimberly Bermel Bonatti and Ethan Uker welcome Dr. Nikhil Palekar, Director of the Stony Brook Center of Excellence for Alzheimer's Disease, to discuss groundbreaking developments in Alzheimer's treatment. Dr. Palekar dives into the recent FDA approval of two new drugs, Lecanemab and Donanemab, which target amyloid plaques in the brain. These plaques are a key feature of Alzheimer's, accumulating years before symptoms appear.
The new medications aim to slow the progression of early-stage Alzheimer's by removing these plaques, offering hope to many patients and their families. Dr. Palekar explains that while these drugs do not cure Alzheimer's, they significantly slow down its progression. Lecanemab has shown a 27% reduction in symptom progression, while Donanemab boasts a 35% reduction. However, he also addresses concerns about side effects like brain swelling and microbleeds, reassuring that most patients experience no long-term neurological issues.
The conversation also touches on the affordability and insurance coverage of these treatments. Despite high costs, Dr. Palekar notes that Medicare covers a significant portion, making these drugs accessible to many. He also shares insights into the mysterious origins of amyloid plaques and the genetic and age-related factors that contribute to Alzheimer's. This episode is packed with valuable information for anyone affected by Alzheimer's or interested in medical advancements. Dr.
Palekar's expertise and the hosts' engaging style make it a must-listen for those seeking hope and understanding in the fight against this challenging disease.